| abstract |
The present invention includes Fcε fragments conjugated with FCη fragments, for example, Fcε1-Hinge-FcE2-FcE3-FcE4-FCy; Hinge-FcE2-FcE3-FcE4- Fcy; FCε2-Fcε3-Fcε4-FCη ; FCε2-Fcε3- Fcη; FCε3-Fcη; and FCε3-Fcε4-FCη , or any derivative or peptide, which has equivalent immunological function. The Fcη fragment may be a fragment of any of the IgG subclasses (lgG1 I IgG2, IgG3, or IgG4), preferably IgG1 or IgG3, wherein the fragment binds FcyRIIB. The present invention also includes compositions suitable for administering to a patient suffering from an allergic disease comprising the fusion protein construct in a pharmaceutical composition including, for example, an excipient, diluant, or carrier. This treatment may be combined with anti-IgE therapy or allergen immunotherapy. |